Metabolic-Associated Steatotic Liver Disease: From Molecular Mechanisms to Novel Therapies
Metabolic-associated steatotic liver disease (MASLD) is a burgeoning worldwide burden and is currently the leading indication for a liver transplant. Despite the growing burden of disease, there are few pharmacological treatments available. The underlying molecular mechanisms of the development of M...
Saved in:
| Main Authors: | John Cooper, Parth Patel, Joven Tristeza, Alexander Yang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | International Journal of Hepatology |
| Online Access: | http://dx.doi.org/10.1155/ijh/5580454 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver diseaseKeypoints
by: Robert F. Schwabe, et al.
Published: (2025-08-01) -
Metabolic dysfunction-associated steatotic liver disease
by: Chieh Chen, et al.
Published: (2024-12-01) -
Mechanism of SIRT2 in Metabolic Dysfunction-associated Steatotic Liver Disease
by: DONG Kaixuan, et al.
Published: (2024-05-01) -
Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome Analysis
by: Gina Ryu, et al.
Published: (2025-01-01) -
Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Myrsini Orfanidou, et al.
Published: (2024-12-01)